A recent systematic review by Wells et al. shows that IDO expression in AML is associated with poor prognosis (244) and measurement of IDO and its kynurenine metabolites may be incorporated into prospective prognostic algorithms (245). This evidence concerns the gene IDO1 and acute myeloid leukemia.